-
Mashup Score: 7Metabolic dysfunction-associated steatotic liver disease: heterogeneous pathomechanisms and effectiveness of metabolism-based treatment - 4 day(s) ago
The global epidemic of metabolic dysfunction-associated steatotic liver disease (MASLD) is increasing worldwide. People with MASLD can progress to cirrhosis and hepatocellular carcinoma and are at increased risk of developing type 2 diabetes, cardiovascular disease, chronic kidney disease, and extrahepatic cancers. Most people with MASLD die from cardiac-related causes. This outcome is attributed to the shared pathogenesis of MASLD and cardiometabolic diseases, involving unhealthy dietary habits, dysfunctional adipose tissue, insulin resistance, and subclinical inflammation.
Source: www.thelancet.comCategories: General Medicine News, EndocrinologyTweet
-
Mashup Score: 1
The ESE Clinical Update on Aggressive Pituitary Tumours 2025 will take place online from Monday 24 March 2025 – Wednesday 26 March 2025.
Source: www.ese-hormones.orgCategories: General Medicine News, EndocrinologyTweet
-
Mashup Score: 1
β-cell replacement is a validated therapy for severe forms of type 1 diabetes.1 In patients with frequent severe hypoglycaemic events, allogeneic pancreatic islet transplantation results in better glycaemic control than insulin therapy alone, enhances quality of life, and reduces and even in some cases eliminates the need for insulin injections.2 Davide Catarinella and colleagues3 from IRCCS Ospedale San Raffaele (Milan, Italy) report the 20-year results of islet transplantation in 79 patients, providing valuable real-world insights into specific risks and long-term outcomes of islet transplantation.
Source: www.thelancet.comCategories: General Medicine News, EndocrinologyTweet
-
Mashup Score: 2Long-term outcomes of pancreatic islet transplantation alone in type 1 diabetes: a 20-year single-centre study in Italy - 4 day(s) ago
This analysis of a large islet transplantation alone cohort provides valuable insights into factors influencing outcomes and highlights potential risks, supporting informed clinical decision making and the optimisation of future β-cell replacement strategies.
Source: www.thelancet.comCategories: General Medicine News, EndocrinologyTweet
-
Mashup Score: 7Realigning diabetes regimens in older adults: a 4S Pathway to guide simplification and deprescribing strategies - 4 day(s) ago
Treating older people with diabetes is challenging due to multiple medical comorbidities that might interfere with patients’ ability to perform self-care. Most diabetes guidelines focus on improving glycaemia through addition of medications, but few address strategies to reduce medication burden for older adults—a concept known as deprescribing. Strategies for deprescribing might include stopping high-risk medications, decreasing the dose, or substituting for less harmful agents. Accordingly, glycaemic management strategies for older adults with type 1 and type 2 diabetes not responding to their current regimen require an understanding of how and when to realign therapy to meet patient’s current needs, which represents a major clinical practice gap.
Source: www.thelancet.comCategories: General Medicine News, EndocrinologyTweet
-
Mashup Score: 5Research Opportunities - 4 day(s) ago
The latest opportunities for advancing endocrinology research
Source: www.endocrine.orgCategories: General Medicine News, EndocrinologyTweet
-
Mashup Score: 0FDA approves two new biosimilars of denosumab-dssb - 5 day(s) ago
The FDA has approved two new biosimilars of denosumab-dssb to treat osteoporosis, increase bone mass, prevent skeletal-related events for people with multiple myeloma and other indications, Samsung Bioepis announced. Ospomyv (Samsung Bioepis) has been approved as a biosimilar referencing the osteoporosis therapy Prolia (Amgen). The biosimilar was approved to treat osteoporosis in postmenopausal
Source: www.healio.comCategories: General Medicine News, EndocrinologyTweet
-
Mashup Score: 4AACE guidance examines medication options for preventing ASCVD in adults with dyslipidemia - 5 day(s) ago
Updated guidance on preventing atherosclerotic cardiovascular disease in people with dyslipidemia includes changes reflecting newer medications that could be added to statin therapy or used on patients intolerant to statins. The American Association of Clinical Endocrinology published in Endocrine Practice an updated guideline on the pharmacologic management of adults with dyslipidemia. This is
Source: www.healio.comCategories: General Medicine News, EndocrinologyTweet
-
Mashup Score: 0Election Ballot Has Launched! - 5 day(s) ago
2025 Election for President-Elect Position Now Open
Source: www.endocrine.orgCategories: General Medicine News, EndocrinologyTweet-
Cast Your Vote for the Next Endocrine Society President | The election for our future President-Elect is now open and Society Members are strongly encouraged to cast your vote. The polls are open until Monday, March 3 at 11:59 PM ET: https://t.co/dGepya6U1Y #endocrinology… https://t.co/Gesuce1F0R https://t.co/SA0dOohWQ7
-
-
Mashup Score: 4Bilateral Adrenal Tumors: A Visual Case Series - 5 day(s) ago
Incidental adrenal masses are common, affecting > 6% of those above 60 years of age and are commonly unilateral and hormonally silent. The incidence of these tumors has risen sharply in recent years, and a minority of patients may have incidentally discovered bilateral masses.1,2 The vast majority of adrenal incidentalomas are benign, nonfunctional tumors of adrenocortical origin; however, these also include hormone-secreting adrenocortical adenomas, adrenocortical carcinomas (ACCs), myelolipomas, pheochromocytomas, adrenal lymphomas, and metastatic disease.
Source: www.aaceclinicalcasereports.comCategories: General Medicine News, EndocrinologyTweet
New—Metabolic dysfunction-associated steatotic liver disease: heterogeneous pathomechanisms and effectiveness of metabolism-based treatment https://t.co/uViLbyUHVf #MASLD #OpenAccess https://t.co/Ld2MKCYhO9